# Treat-and-extend Using Aflibercept for Type 3 Neovascularization

> **NCT04655482** · PHASE4 · UNKNOWN · sponsor: **Kim's Eye Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Retinal Angiomatous Proliferation

## Interventions

- **DRUG:** Aflibercept Injection

## Key facts

- **NCT ID:** NCT04655482
- **Lead sponsor:** Kim's Eye Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2023-12-20
- **Final completion:** 2024-08-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655482, "Treat-and-extend Using Aflibercept for Type 3 Neovascularization". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04655482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*